Drugs / ω3 PUFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02691533 | Feb 2016 → Dec 2017 | chronic liver failure | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ω3 PUFA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02691533 ↗ |
| Known as | Omegavan | “Group A subjects will receive ω3 PUFA (Polyunsaturated Fatty Acids) (10% Omegavan 100 ml).” NCT02691533 ↗ |